By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French biopharmaceutical firm Transgene today announced Beckman Coulter will develop a companion diagnostic for Transgene to measure levels of activated Natural Killer (aKN) cells so that patients can be selected for treatment with an immunotherapy candidate for non-small cell lung cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.